Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Azaya Therapeutics, Inc. Elects Ze’ev Shaked, Ph.D., to Board of Directors

Abstract:
Brings Track Record of Successful Product Commercialization

Azaya Therapeutics, Inc. Elects Ze’ev Shaked, Ph.D., to Board of Directors

SAN ANTONIO, TX | Posted on May 31st, 2007

Azaya Therapeutics, Inc. today announced the election of Dr. Ze'ev Shaked to its Board of Directors. Dr. Shaked has extensive managerial and pharmaceutical product development experience in commercializing new drug products. He most recently was President and CEO of Spherics, Inc., where he transformed the company into a product-driven company with an attractive product pipeline, and where he raised more than $25 million from the venture capital industry.

Prior to Spherics, Dr. Shaked was Chief Operating Officer of ILEX Oncology, Inc., in San Antonio, Texas. He was instrumental in ILEX obtaining ownership and FDA approval for CAMPATH and Clolar, two of its commercialized products. In addition, Dr. Shaked has held a number of senior research and development and corporate management positions at ImmuLogic Pharmaceutical Corporation, Berlex Biosciences, Inc., Triton Biosciences, Inc., CODON Corporation, and Chiron Corporation. He obtained his Ph.D. in Organic Chemistry and Applied Biochemistry from the Massachusetts Institute of Technology.

"Ze'ev Shaked has an outstanding track record in the biopharmaceutical industry and in overseeing the development of new drugs," said John Kerr, chairman of the board of Azaya. "His wealth of scientific experience will be invaluable in guiding the overall development of Azaya's pipeline of products."

####

About Azaya Therapeutics, Inc.
Azaya Therapeutics, Inc., is an emerging nanotherapy company with an innovative technology platform – Protein Stabilized Nanoparticles – (PSNTM) designed to significantly improve the efficacy and safety of water insoluble pharmaceutical agents. Azaya is initially building an in-house pipeline of safer and more efficacious nanoparticle chemotherapy drug products. Azaya was granted a patent on this technology in February 2007.

For more information, please click here

Contacts:
Azaya Therapeutics, San Antonio
Michael T. Dwyer, 210-341-6600
or
Dublin & Associates
Eric Whittington, 210-227-0221, ext. 239

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

Announcements

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project